This is a retrospective study to evaluate the results of our early experience of using doxorubicin eluting beads (DEB) to treat patients with early and intermediate hepatocellular carcinoma (HCC).
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.